Endocyte (ECYT) Misses Q1 EPS by 2c

Endocyte (NASDAQ: ECYT) reported Q1 EPS of ($0.26), $0.02 worse than the analyst estimate of ($0.24).

Cash, cash equivalents and investments were $196.8 million at March 31, 2015, compared to $206.8 million at December 31, 2014, and $131.5 million at March 31, 2014.

"We have successfully moved both EC1456, a folate-targeted tubulysin, and EC1169, a prostate-specific membrane antigen (PSMA)-targeted tubulysin, into the fifth cohorts of their respective dose escalation trials," said Ron Ellis, Endocyte's president and chief executive officer. "We're evaluating both drugs in two different dosing schedules, which will inform our approach to expanding these trials as we reach the maximum tolerated dose. We look forward to reporting data from the Phase 1 dose escalation trials at upcoming medical conferences, and beginning the expansion phase of these trials in the second half of 2015."

For earnings history and earnings-related data on Endocyte (ECYT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c